Free Trial
NYSE:DGX

Quest Diagnostics (DGX) Stock Price, News & Analysis

Quest Diagnostics logo
$190.74 +0.56 (+0.29%)
Closing price 05/13/2026 03:59 PM Eastern
Extended Trading
$190.92 +0.19 (+0.10%)
As of 05/13/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Quest Diagnostics Stock (NYSE:DGX)

Advanced

Key Stats

Today's Range
$187.51
$191.11
50-Day Range
$187.43
$208.23
52-Week Range
$164.65
$213.50
Volume
693,136 shs
Average Volume
1.05 million shs
Market Capitalization
$21.11 billion
P/E Ratio
21.08
Dividend Yield
1.80%
Price Target
$216.58
Consensus Rating
Moderate Buy

Company Overview

Quest Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

DGX MarketRank™: 

Quest Diagnostics scored higher than 97% of companies evaluated by MarketBeat, and ranked 26th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Quest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 7 hold ratings, and no sell ratings.

  • Upside Potential

    Quest Diagnostics has a consensus price target of $216.58, representing about 13.5% upside from its current price of $190.74.

  • Amount of Analyst Coverage

    Quest Diagnostics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Quest Diagnostics' stock forecast and price target.
  • Earnings Growth

    Earnings for Quest Diagnostics are expected to grow by 7.64% in the coming year, from $10.73 to $11.55 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Quest Diagnostics is 21.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.36.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Quest Diagnostics is 21.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.23.

  • Price to Earnings Growth Ratio

    Quest Diagnostics has a PEG Ratio of 2.26. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Quest Diagnostics has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Quest Diagnostics' valuation and earnings.
  • Percentage of Shares Shorted

    3.09% of the float of Quest Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Quest Diagnostics has a short interest ratio ("days to cover") of 2.59, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Quest Diagnostics has recently decreased by 4.56%, indicating that investor sentiment is improving.
  • Dividend Yield

    Quest Diagnostics pays a meaningful dividend of 1.81%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Quest Diagnostics has been increasing its dividend for 14 years.

  • Dividend Coverage

    The dividend payout ratio of Quest Diagnostics is 38.01%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 29.78% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.

  • Read more about Quest Diagnostics' dividend.
  • News Sentiment

    Quest Diagnostics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Quest Diagnostics this week, compared to 7 articles on an average week.
  • Search Interest

    16 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,790,214.00 in company stock.

  • Percentage Held by Insiders

    0.88% of the stock of Quest Diagnostics is held by insiders.

  • Percentage Held by Institutions

    88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Quest Diagnostics' insider trading history.
Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DGX Stock News Headlines

Read this warning immediately
Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
DGX Stock Price Prediction
Quest Diagnostics Incorporated
See More Headlines

DGX Stock Analysis - Frequently Asked Questions

Quest Diagnostics' stock was trading at $173.47 at the start of the year. Since then, DGX stock has increased by 10.0% and is now trading at $190.7390.

Quest Diagnostics Incorporated (NYSE:DGX) posted its quarterly earnings data on Tuesday, April, 21st. The medical research company reported $2.50 earnings per share for the quarter, topping analysts' consensus estimates of $2.37 by $0.13. The firm's revenue was up 9.2% on a year-over-year basis.
Read the conference call transcript
.

Quest Diagnostics' Board of Directors approved a stock repurchase plan on Tuesday, February 10th 2026, which authorizes the company to repurchase $1,000,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 4.7% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's leadership believes its stock is undervalued.

Quest Diagnostics subsidiaries include MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and more.

Quest Diagnostics (DGX) raised $12 million in an initial public offering (IPO) on Tuesday, January 7th 2025. The company issued 2,300,000 shares at a price of $4.00-$6.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO.

Quest Diagnostics' top institutional shareholders include Dimensional Fund Advisors LP (1.76%), Bank of New York Mellon Corp (0.59%), Principal Financial Group Inc. (0.48%) and First Trust Advisors LP (0.30%). Insiders that own company stock include J E Davis, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Gary M Pfeiffer, Vicky B Gregg, Patrick Plewman, Karthik Kuppusamy and Mark E Delaney.
View institutional ownership trends
.

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

Record date for 4/20 Dividend
4/06/2026
Ex-Dividend for 4/20 Dividend
4/06/2026
Dividend Payable
4/20/2026
Last Earnings
4/21/2026
Today
5/13/2026
Next Earnings (Estimated)
7/28/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - OUTP/HM CRE
Sub-Industry
Health Care Services
Current Symbol
NYSE:DGX
CIK
1022079
Employees
57,000
Year Founded
1967

Price Target and Rating

High Price Target
$235.00
Low Price Target
$178.00
Potential Upside/Downside
+13.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
$9.05
Trailing P/E Ratio
21.08
Forward P/E Ratio
17.78
P/E Growth
2.26
Net Income
$992 million
Net Margins
9.07%
Pretax Margin
12.20%
Return on Equity
15.60%
Return on Assets
7.06%

Debt

Debt-to-Equity Ratio
0.67
Current Ratio
1.18
Quick Ratio
1.08

Sales & Book Value

Annual Sales
$11.04 billion
Price / Sales
1.91
Cash Flow
$15.22 per share
Price / Cash Flow
12.53
Book Value
$69.25 per share
Price / Book
2.75

Miscellaneous

Outstanding Shares
110,700,000
Free Float
109,722,000
Market Cap
$21.11 billion
Optionable
Optionable
Beta
0.60

Social Links

The 10 Best AI Stocks to Own in 2026 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:DGX) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners